Literature DB >> 29701875

Estimation of the optimal surrogate based on a randomized trial.

Brenda L Price1, Peter B Gilbert1,2, Mark J van der Laan3.   

Abstract

A common scientific problem is to determine a surrogate outcome for a long-term outcome so that future randomized studies can restrict themselves to only collecting the surrogate outcome. We consider the setting that we observe n independent and identically distributed observations of a random variable consisting of baseline covariates, a treatment, a vector of candidate surrogate outcomes at an intermediate time point, and the final outcome of interest at a final time point. We assume the treatment is randomized, conditional on the baseline covariates. The goal is to use these data to learn a most-promising surrogate for use in future trials for inference about a mean contrast treatment effect on the final outcome. We define an optimal surrogate for the current study as the function of the data generating distribution collected by the intermediate time point that satisfies the Prentice definition of a valid surrogate endpoint and that optimally predicts the final outcome: this optimal surrogate is an unknown parameter. We show that this optimal surrogate is a conditional mean and present super-learner and targeted super-learner based estimators, whose predicted outcomes are used as the surrogate in applications. We demonstrate a number of desirable properties of this optimal surrogate and its estimators, and study the methodology in simulations and an application to dengue vaccine efficacy trials.
© 2018 The Authors. Biometrics published by Wiley Periodicals, Inc. on behalf of International Biometric Society.

Entities:  

Keywords:  Asymptotic linearity; Cross-validation; Efficient influence curve; Prentice definition of a valid surrogate; Semiparametric model; Super-learner; Targeted maximum likelihood; Targeted minimum loss based estimation

Mesh:

Substances:

Year:  2018        PMID: 29701875      PMCID: PMC6393111          DOI: 10.1111/biom.12879

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  10 in total

1.  Principal stratification in causal inference.

Authors:  Constantine E Frangakis; Donald B Rubin
Journal:  Biometrics       Date:  2002-03       Impact factor: 2.571

2.  Efficacy of a tetravalent dengue vaccine in children in Latin America.

Authors:  Luis Villar; Gustavo Horacio Dayan; José Luis Arredondo-García; Doris Maribel Rivera; Rivaldo Cunha; Carmen Deseda; Humberto Reynales; Maria Selma Costa; Javier Osvaldo Morales-Ramírez; Gabriel Carrasquilla; Luis Carlos Rey; Reynaldo Dietze; Kleber Luz; Enrique Rivas; Maria Consuelo Miranda Montoya; Margarita Cortés Supelano; Betzana Zambrano; Edith Langevin; Mark Boaz; Nadia Tornieporth; Melanie Saville; Fernando Noriega
Journal:  N Engl J Med       Date:  2014-11-03       Impact factor: 91.245

3.  The validation of surrogate endpoints in meta-analyses of randomized experiments.

Authors:  M Buyse; G Molenberghs; T Burzykowski; D Renard; H Geys
Journal:  Biostatistics       Date:  2000-03       Impact factor: 5.899

4.  Identifiability and exchangeability for direct and indirect effects.

Authors:  J M Robins; S Greenland
Journal:  Epidemiology       Date:  1992-03       Impact factor: 4.822

5.  Super learner.

Authors:  Mark J van der Laan; Eric C Polley; Alan E Hubbard
Journal:  Stat Appl Genet Mol Biol       Date:  2007-09-16

6.  Discussion on "surrogate measures and consistent surrogates".

Authors:  Marshall M Joffe
Journal:  Biometrics       Date:  2013-09       Impact factor: 2.571

7.  Related causal frameworks for surrogate outcomes.

Authors:  Marshall M Joffe; Tom Greene
Journal:  Biometrics       Date:  2009-06       Impact factor: 2.571

8.  Meta-analysis for the evaluation of potential surrogate markers.

Authors:  M J Daniels; M D Hughes
Journal:  Stat Med       Date:  1997-09-15       Impact factor: 2.373

9.  Surrogate endpoints in clinical trials: definition and operational criteria.

Authors:  R L Prentice
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

10.  Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.

Authors:  Maria Rosario Capeding; Ngoc Huu Tran; Sri Rezeki S Hadinegoro; Hussain Imam H J Muhammad Ismail; Tawee Chotpitayasunondh; Mary Noreen Chua; Chan Quang Luong; Kusnandi Rusmil; Dewa Nyoman Wirawan; Revathy Nallusamy; Punnee Pitisuttithum; Usa Thisyakorn; In-Kyu Yoon; Diane van der Vliet; Edith Langevin; Thelma Laot; Yanee Hutagalung; Carina Frago; Mark Boaz; T Anh Wartel; Nadia G Tornieporth; Melanie Saville; Alain Bouckenooghe
Journal:  Lancet       Date:  2014-07-10       Impact factor: 79.321

  10 in total
  7 in total

1.  Inference on treatment effect modification by biomarker response in a three-phase sampling design.

Authors:  Michal Juraska; Ying Huang; Peter B Gilbert
Journal:  Biostatistics       Date:  2020-07-01       Impact factor: 5.899

Review 2.  Clinical artificial intelligence quality improvement: towards continual monitoring and updating of AI algorithms in healthcare.

Authors:  Jean Feng; Rachael V Phillips; Ivana Malenica; Andrew Bishara; Alan E Hubbard; Leo A Celi; Romain Pirracchio
Journal:  NPJ Digit Med       Date:  2022-05-31

3.  Estimation of the proportion of treatment effect explained by a high-dimensional surrogate.

Authors:  Ruixuan Rachel Zhou; Sihai Dave Zhao; Layla Parast
Journal:  Stat Med       Date:  2022-02-21       Impact factor: 2.497

4.  Testing for heterogeneity in the utility of a surrogate marker.

Authors:  Layla Parast; Tianxi Cai; Lu Tian
Journal:  Biometrics       Date:  2021-12-07       Impact factor: 1.701

5.  Quantifying the feasibility of shortening clinical trial duration using surrogate markers.

Authors:  Xuan Wang; Tianxi Cai; Lu Tian; Florence Bourgeois; Layla Parast
Journal:  Stat Med       Date:  2021-09-02       Impact factor: 2.373

Review 6.  The concept of justifiable healthcare and how big data can help us to achieve it.

Authors:  Wim van Biesen; Catherine Van Der Straeten; Sigrid Sterckx; Johan Steen; Lisa Diependaele; Johan Decruyenaere
Journal:  BMC Med Inform Decis Mak       Date:  2021-03-06       Impact factor: 2.796

7.  Evaluating multiple surrogate markers with censored data.

Authors:  Layla Parast; Tianxi Cai; Lu Tian
Journal:  Biometrics       Date:  2020-09-22       Impact factor: 2.571

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.